The rural communities of the upper Midwest and Central Plains represent a large underserved population for cancer treatment, care delivery and clinical trials. The causes of this difference are multi-factorial but a main obstacle is access to services in rural regional areas. Sanford Health has developed a network of hospitals, cancer centers and clinics to provide high quality multi-disciplinary cancer treatment, clinical trials, ad cancer care delivery to this underserved area. It is hypothesized that this disparity in care for this rural population can be improved by utilizing the organized Sanford Community Cancer Program (SCCP) network community. This proposal describes the NCI NCORP partnership to help deliver clinical trials and cancer care delivery across the rural area the SCCP serves. This will be accomplished through the following aims: 1. /Maintain and enhance robust accrual to NCI Division of Cancer Prevention (DCP) supported clinical trials through our five primary components. 2. Address disparities in clinical trial accrual in underserved and underrepresented populations to increase participation. 3. Cultivate Innovative access points to address barriers to clinical trial accrual through outreach and telemedicine. 4. Develop a Cancer Care Delivery infrastructure. Through these four aims the Sanford Community Cancer Program will transform implementation of state of the art clinical trials, cancer treatment and cancer care delivery to approximately two million people across parts of five states living in rura America. Many of these people are more than 2 hours from the nearest community cancer center, a situation complicated by 4 to 6 months of harsh weather, which can make travel unpredictable and often dangerous. The ability to provide cancer care, including clinical trials, through outreach and telemedicine to this underserved rural population in their local communities ensures timely, optimal treatment and improved outcomes.
the Sanford Community Cancer Program will continue to offer NCI clinical trials and provide state-of-the-art cancer treatment and cancer care delivery to approximately two million people across six states ability to provide clinical trials through outreach and telemedicine to this underserved rural population of patients increases their opportunity for participation in a trial as a treatment option. As a community based health care organization, the SCCP will participate in the development and implementation of cancer care delivery research to better understand and improve patient outcomes.
|McCleary, Nadine J; Hubbard, Joleen; Mahoney, Michelle R et al. (2018) Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). J Geriatr Oncol 9:24-31|
|McWilliams, Robert R; Allred, Jacob B; Slostad, Jessica A et al. (2018) NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab?±?everolimus for metastatic melanoma. Cancer 124:537-545|
|Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58|
|McWilliams, Robert R; Foster, Nathan R; Mahoney, Michelle R et al. (2017) North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma. Cancer 123:3494-3501|
|Schild, Steven E; Hillman, Shauna L; Tan, Angelina D et al. (2017) Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). J Thorac Oncol 12:697-703|
|Bhatia, Aarti K; Lee, Ju-Whei; Pinto, Harlan A et al. (2017) Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer 123:4653-4662|
|Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527|
|Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A et al. (2016) Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol 17:1661-1671|
|Navari, Rudolph M; Qin, Rui; Ruddy, Kathryn J et al. (2016) Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 375:134-42|
|Park, Haeseong; Qin, Rui; Smith, Thomas J et al. (2015) North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause 22:627-32|
Showing the most recent 10 out of 11 publications